Amylin Pharmaceuticals, Inc.

Bionebraska, Inc.

Tina Vilsboll

Jens J Holst

J J Holst

Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in &#x3b2;-cell stimulatory tests in order to test &#x3b2;-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.

GLP-1 as a diagnostic test to determine &#x3b2;-cell function and the presence of the condition of IGT and type-II diabetes

Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in &bgr;-cell stimulatory tests in order to test &bgr;-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.

Growing community of inventors

Hellerup, Denmark

Tina Vilsboll